Compare Newegg Commerce Inc (NEGG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Novo Nordisk A/S — how do they compare? Newegg Commerce Inc trades at $11.58 (market cap $243.30M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 679.4× Newegg Commerce Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and Novo Nordisk A/S for 116 Days on average.
| NEGG | NVO | |
|---|---|---|
Market Cap | $243.30M | $165.31B |
Volume | 41,252 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $63.98 |
52-Week Low | $11.49 | $35.29 |
Typical Hold Time | 14 Days | 116 Days |
Enterprise Value | $213.53M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $11.58, down 3.58% on the day, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.11 versus a -$0.40 estimate. The company shows improving fundamentals, with revenue stabilizing around $1.4B and net losses narrowing significantly in 2025. New partnerships with Western Digital and Hewlett Packard Enterprise highlight strategic moves in IT infrastructure.
The outlook is mixed; improving profitability and low P/S ratio offer value, but negative operating cash flow and insider selling pose risks. Analyst consensus is a Buy with a $7.75 target, below the current price, indicating caution. Key risks include competitive pressures and reliance on financing activities for liquidity.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
